GlassScriptPhysician profile
Heaven A Robbins
NPI 1689185464
$9,263.04
in general payments reported to CMS, 2019-2025
45 companies · $1,497 in 2025
The $1,497 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,819 · 2022: $2,158 · 2023: $2,189 · 2024: $1,600 · 2025: $1,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,285.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,521.60 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,032.20 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $761.30 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $663.90 | 2021-2025 | |
| Lilly USA, LLC | $526.68 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $438.37 | 2022-2025 | Caplyta |
| Novo Nordisk INC | $412.47 | 2021-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $342.83 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.05 | 2021-2023 | Jardiance, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $259.52 | 2021-2024 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $258.05 | 2022 | |
| Sk Life Science, INC. | $234.95 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $212.28 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $205.91 | 2021-2025 | Rexulti |
| Amgen INC. | $188.26 | 2022-2025 | Otezla, Repatha, Otezla |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $160.76 | 2021-2023 | Spravato |
| Abbott Laboratories | $157.29 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Mylan Specialty L.P. | $153.92 | 2021-2024 | Yupelri |
| Biohaven Pharmaceuticals, INC. | $115.31 | 2021 | |
| Sanofi-Aventis U.S. LLC | $115.21 | 2021-2022 | |
| Biogen, INC. | $111.94 | 2021 | |
| Dexcom, INC. | $94.22 | 2022-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $91.30 | 2024-2025 | Rexulti |
| Esperion Therapeutics, INC. | $89.69 | 2021-2024 | Nexletol |
| Amarin Pharma, INC. | $82.05 | 2021 | |
| Merck Sharp & Dohme LLC | $72.02 | 2021-2025 | Capvaxive, Gardasil 9 |
| Supernus Pharmaceuticals, INC. | $71.65 | 2021-2025 | Qelbree |
| Phathom Pharmaceuticals, INC. | $71.58 | 2024 | Voquezna |
| Boston Scientific Corporation | $66.82 | 2022-2025 | Watchman Flx, Watchman Access System |
| Ardelyx, INC. | $64.67 | 2024-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $58.19 | 2021-2024 | |
| Corium, LLC | $38.97 | 2022 | |
| Astellas Pharma US INC | $34.03 | 2021-2024 | Veozah |
| Daiichi Sankyo INC. | $32.76 | 2021-2022 | |
| Eisai INC. | $31.99 | 2021 | |
| Xeris Pharmaceuticals, INC. | $24.46 | 2025 | Recorlev |
| Idorsia Pharmaceuticals US INC | $21.02 | 2022 | |
| Sunovion Pharmaceuticals INC. | $17.36 | 2021 | |
| Tris Pharma INC | $15.07 | 2024 | Dyanavel Xr |
| Sanofi Pasteur INC. | $14.88 | 2025 | |
| Shield Therapeutics INC | $14.87 | 2024 | |
| Ucb, INC. | $13.77 | 2021 | |
| Ironshore Pharmaceuticals INC. | $13.48 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.67 | 2021 | |
| Bausch Health US, LLC | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heaven Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.